Intensity-modulated stereotactic body radiotherapy with simultaneous integrated-boost in patients with bone metastasis of the spine

Intensity-modulated stereotactic body radiotherapy with simultaneous integrated-boost in patients with bone metastasis of the spine - SIB-IM-SBRT for bone metastasis of the spine

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000041948

Enrollment

Registered

2020-10-01

Start date

2020-09-26

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bone metastasis of the spine

Interventions

The patients with spinal bone metastases will receive SIB-IM-SBRT with 30 Gy in 5 fractions.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Patients with bone metastasis of the spine 2.Life expectancy of at least 1 year 3.Aged 20<= years 4.ECOG performance status 0-2 5.Written informed consent

Exclusion criteria

Exclusion criteria: 1.Patients who had a previous RT to the treatment area 2.Dose constraints of organs at risk are not observed 3.Patients requiring radiotherapy for oncologic emergencies 4.Cases that the dose distribution can not be evaluated exactly. 5.Patients who have psychosis or psychiatric symptoms that interferes with daily life 6.Patients who are unsuitable for enrolment into the study by the investigator's judgment.

Design outcomes

Primary

Measure	Time frame
1-year local control rate	—

Secondary

Measure	Time frame
Acute and late adverse events Progression free survival Overall survival	—

Countries

Japan

Contacts

Public ContactTakamasa Mitsuyoshi

Kobe City Medical Center General Hospital Department of Radiation Oncology

mitsu.t@kuhp.kyoto-u.ac.jp078-302-4321

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026